135 related articles for article (PubMed ID: 38334069)
21. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
22. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
23. US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
Bassali J; Gould IG; Kaye JA; Mladsi D; Mehta J
Clinicoecon Outcomes Res; 2020; 12():317-325. PubMed ID: 32606848
[TBL] [Abstract][Full Text] [Related]
24. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
[TBL] [Abstract][Full Text] [Related]
25. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
26. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
27. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
28. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
[TBL] [Abstract][Full Text] [Related]
29. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States.
Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T
J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141
[TBL] [Abstract][Full Text] [Related]
30. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
31. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
Burudpakdee C; Shah A; Joish VN; Divers C; Yaldo A
Am Health Drug Benefits; 2014 Dec; 7(9):479-87. PubMed ID: 25610527
[TBL] [Abstract][Full Text] [Related]
32. Health plan budget impact analysis for pimecrolimus.
Chang J; Sung J
J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
[TBL] [Abstract][Full Text] [Related]
34. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.
Kongnakorn T; Bharmal M; Kearney M; Phatak H; Benedict A; Bhanegaonkar A; Galsky M
Clinicoecon Outcomes Res; 2019; 11():659-672. PubMed ID: 31807039
[TBL] [Abstract][Full Text] [Related]
35. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma.
Dolph M; Tremblay G; Leong H
Clinicoecon Outcomes Res; 2021; 13():493-502. PubMed ID: 34140789
[TBL] [Abstract][Full Text] [Related]
36. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
[TBL] [Abstract][Full Text] [Related]
37. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
[TBL] [Abstract][Full Text] [Related]
38. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
Baker CL; Ferrufino CP; Bruno M; Kowal S
Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
[TBL] [Abstract][Full Text] [Related]
39. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
40. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
